192Ir近距离放疗联合外照射及胆道支架治疗不能手术切除的肝门部胆管癌的应用探索n

来源 :国际肿瘤学杂志 | 被引量 : 0次 | 上传用户:bianyuantuifei
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:评价n 192Ir近距离放疗联合外照射治疗不能手术切除的肝门部胆管癌的疗效及安全性。n 方法:回顾分析2016年2月至2018年7月河北省沧州中西医结合医院收治的26例不能手术切除的肝门部胆管癌患者的临床资料。所有患者均接受n 192Ir近距离放疗联合外照射,首先给予经皮肝胆道支架置入,然后行外照射放疗(放疗剂量45 Gy,分25次),再给予n 192Ir近距离放疗(放疗剂量20 Gy,分4次),并化疗4~6个周期。评价近期及远期疗效,并分析治疗前后Karnofsky功能状态(KPS)评分、CA19-9、总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平变化及经皮肝穿胆道引流(PTCD)管留置时间。根据美国肿瘤放射治疗协作组织(RTOG)损伤分级标准记录不良反应。n 结果:治疗结束3个月后,完全缓解4例(15.4%),部分缓解20例(76.9%),病情稳定2例(7.7%),无疾病进展患者,客观缓解率为92.3%(24/26)。1年、2年局部控制率分别为75.0%、62.5%,1年、2年总生存率分别为57.7%、26.9%。治疗结束1个月KPS评分为70.39±10.76,较治疗前60.00±10.58明显升高(n t=-27.00,n P<0.001)。治疗前及治疗结束1个月、2个月、3个月CA19-9水平分别为(390.88±202.62)U/ml、(322.45±204.06)U/ml、(254.00±160.49)U/ml、(182.85±124.05)U/ml,呈现逐渐下降的趋势,差异具有统计学意义(n F=126.94,n P<0.001);TBIL[(250.88±80.83)μmol/L、(153.98±61.74)μmol/L、(93.45±38.12)μmol/L、(53.82±26.75)μmol/L]、DBIL[(205.82±66.68)μmol/L、(133.23±58.53)μmol/L、(64.31±36.25)μmol/L、(40.55±26.16)μmol/L]、ALT[(163.92±54.12)U/L、(68.23±28.86)U/L、(45.73±21.94)U/L、(32.66±12.88)U/L]、AST[(177.69±58.68)U/L、(79.23±32.87)U/L、(49.77±25.45)U/L、(35.54±16.10)U/L]均呈进行性下降,差异均有统计学意义(n F=315.60,n P<0.001;n F=385.30,n P<0.001;n F=284.24,n P<0.001;n F=311.80,n P<0.001),肝功能得以改善。所有患者治疗后均拔除PTCD管,拔管中位时间54 d(49~96 d)。治疗期间出现骨髓抑制、恶心呕吐、腹部胀痛、胆道感染等不良反应,给予对症治疗后均好转,未发生胆漏、胆道出血等严重并发症。n 结论:192Ir近距离放疗联合外照射治疗不能手术切除的肝门部胆管癌疗效可靠,可改善患者生命质量,不良反应可耐受,为临床提供了一种可行、安全的治疗方法。n “,”Objective:To evaluate the efficacy and safety of n 192Ir brachytherapy combined with external beam radiation for the treatment of unresectable hilar cholangiocarcinoma.n Methods:The clinical data of 26 patients with unresectable hilar cholangiocarcinoma admitted to Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine from February 2016 to July 2018 were retrospectively analyzed. All patients received n 192Ir brachytherapy combined with external beam radiation. First, percutaneous hepatobiliary stent implantation was given, followed by external beam radiotherapy (radiotherapy dose 45 Gy, 25 times), and then n 192Ir brachytherapy (radiotherapy dose 20 Gy, 4 times), a total of 4 to 6 cycles of chemotherapy. The short-term and long-term efficacy were evaluated, and the Karnofsky performance status (KPS) score, CA19-9, total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST) level changes and percutaneous transhepatic biliary drainage (PTCD) tube indwelling time were analyzed. Adverse reactions were recorded according to the Radiation Therapy Oncology Group (RTOG) injury classification standard.n Results:Three months after the end of treatment, 4 cases (15.4%) were completely remitted, 20 cases (76.9%) were partially remitted, 2 cases (7.7%) were stable, and there was no disease progression. The objective remission rate was 92.3% (24/26). The 1-year and 2-year local control rates were 75.0% and 62.5% respectively, and the 1-year and 2-year overall survival rates were 57.7% and 26.9% respectively. The KPS score was 70.39±10.76 one month after the treatment, which was significantly higher than the 60.00±10.58 before treatment (n t=-27.00, n P<0.001). The levels of CA19-9 before treatment and 1 month, 2 months and 3 months after treatment were (390.88±202.62) U/ml, (322.45±204.06) U/ml, (254.00±160.49) U/ml, (182.85±124.05) U/ml, which showed a gradual decrease trend, and there was a statistically significant difference (n F=126.94, n P<0.001). TBIL [(250.88±80.83) μmol/L, (153.98±61.74) μmol/L, (93.45±38.12) μmol/L, (53.82±26.75) μmol/L], DBIL [(205.82±66.68) μmol/L, (133.23±58.53) μmol/L, (64.31±36.25) μmol/L, (40.55±26.16) μmol/L], ALT [(163.92±54.12) U/L, (68.23±28.86) U/L, (45.73±21.94) U/L, (32.66±12.88) U/L], AST [(177.69±58.68) U/L, (79.23±32.87) U/L, (49.77±25.45) U/L, (35.54±16.10) U/L] showed progressive decline, with statistically significant differences (n F=315.60, n P<0.001;n F=385.30, n P<0.001;n F=284.24, n P<0.001;n F=311.80, n P<0.001), and liver function was improved. The PTCD tube was removed after treatment in all patients, with a median time of 54 days (49-96 days). During the treatment, bone marrow suppression, nausea and vomiting, abdominal pain and biliary tract infection occurred. All of them improved after symptomatic treatment. No serious complications such as bile leakage and biliary hemorrhage occurred.n Conclusion:192Ir brachytherapy combined with external beam radiation has a reliable curative effect in the treatment of unresectable hilar cholangiocarcinoma. It can improve the quality of life of patients, and the adverse reactions can be tolerated. It provides a feasible and safe treatment method for the clinic.n
其他文献
目的:探讨人16号染色体长臂(16q)缺失相关差异表达基因(DEGs)和miRNAs(DEmiRs)对肝癌细胞增殖、迁移和凋亡及肝细胞癌(HCC)患者预后的影响及其机制.方法:从肿瘤与癌症基因组图谱(TCGA)数据库的HCC数据集中获取全转录组数据和拷贝数变异(CNV)数据,就16q缺失对数据集进行DEGs和DEmiRs筛选;从Kaplan-Meier Plotter数据库中获取DEGs对患者生存影响图谱;通过miRWalk网站预测DEGs表达调节相关的miRNAs.构建miRNA mimic慢病毒载体转
目的:利用慢病毒质粒构建细胞分裂周期蛋白25(CDC25)表达下调的黑色素瘤B16细胞,探讨CDC25C表达下调对黑色素瘤细胞自噬和迁移能力的影响.方法:利用TCGA可视化在线工具GEPIA数据库检测CDC25C在黑色素瘤中的表达;通过慢病毒质粒转染构建CDC25C表达下调的黑色素瘤B16细胞株,并以RT-qPCR技术确认其表达量;以RT-qPCR和Western blotting方法检测CDC25C表达下调对自噬相关分子p62、LC3及beclin1的影响;划痕修复实验观察CDC25C表达下调对B16细
目的:探讨白藜芦醇(RSV)对脂多糖(LPS)诱导的HT-29细胞紧密连接蛋白损伤的作用及机制.方法:体外培养人结肠癌上皮HT-29细胞,CCK-8法检测不同浓度LPS、RSV和γ-分泌酶抑制剂(DAPT)对细胞活力的影响.将HT-29细胞分为对照组、LPS组、RSV低剂量组、RSV高剂量组和Notch1通路抑制剂组(即DAPT组).采用Western blotting检测各组细胞紧密连接蛋白occludin、ZO-1、claudin-1和Notch1通路上Notch1及Hes1蛋白的表达.结果:LPS、
目的:探究聚腺苷二磷酸核糖聚合酶-1(PARP-1)对缺氧/复氧(H/R)诱导的心肌细胞损伤的作用及其机制.方法:体外培养大鼠心肌细胞H9c2,将其分为对照组、H/R组、PARP-1特异性抑制剂氨基苯甲酰胺(3-AB)处理组(3-AB组)、3-AB+过表达空载(3-AB+oe-NC)组和3-AB+过表达HMGB1(3-AB+oe-HMGB1)组.除对照组外,其他各组均予H/R处理.采用CCK-8法检测细胞活力,EdU实验检测细胞增殖,流式细胞术检测细胞凋亡,免疫沉淀法检测HMGB1乙酰化,免疫荧光染色检测
目的:探讨氯胺酮通过p38 MAPK信号通路对乳腺癌细胞增殖、侵袭与迁移的影响.方法:以乳腺癌细胞MDA-MB-231为研究对象,根据细胞培养基添加氯胺酮和p38 MAPK抑制剂(SB203580)分为4组:control组(无氯胺酮和SB203580)、氯胺酮组(10μg/mL)、SB203580组(20μmol/L)、氯胺酮+SB203580组(氯胺酮10μg/mL+SB20358020μmol/L);实时荧光定量PCR(RT-qPCR)法检测各组细胞中p38 MAPK磷酸化水平;克隆形成实验检测各组
目的:分析白细胞分化抗原6(CD6)与进展性慢性肾脏病(CKD)的相关性,预测其作用机制.方法:利用GEO数据库芯片数据及临床资料分析CD6与CKD的相关性,基因功能和通路富集分析和应用CIBERSORT工具评估CD6表达与免疫细胞浸润的相关性.构建小鼠单侧输尿管结扎纤维化模型验证CD6与肾小管纤维化的相关性.结果:CD6 mRNA在进展性CKD中显著升高,是CKD进展的独立预测风险因素(HR=3.67,P<0.001);ROC曲线下面积(AUC值)1年、3年、5年分别为0.877、0.853和0.948
目的:探讨高脂对肝癌细胞E2F1、细胞侵袭及迁移的影响.方法:将HepG2肝癌细胞分为对照组和高脂组,分别用不含游离脂肪酸(FFA)培养基和含1 mmol/L FFA(油酸:棕榈酸=2:1)培养基培养;采用划痕实验和Transwell迁移、侵袭实验来比较两组细胞的迁移和侵袭能力;采用Western blotting实验和RT-qPCR实验检测E2F1和上皮间质转化(EMT)相关标志物(α-SMA、Vimentin、β-catenin、E-cadherin)的蛋白表达以及mRNA水平;使用Spearman相
目的:比较不同品系小鼠哮喘模型的差异.方法:将BALB/c和C57BL/6两品系雄鼠随机分为对照组与哮喘组,每组6只.采用卵清蛋白(OVA)和氢氧化铝混悬液致敏和激发小鼠,激发过程中观察小鼠哮喘症状.取支气管肺泡灌洗液(BALF)进行细胞分类计数,酶联免疫吸附试验(ELISA)法检测白介素(IL)-4和干扰素(IFN)-γ浓度,苏木精—伊红(HE)染色及过碘酸雪夫(PAS)染色观察肺组织病理学改变.Western blotting及免疫组织化学染色法检测肺组织中NOD样受体蛋白3(NL-RP3)、casp
目的:研究miR-877对血红蛋白诱导的离体星形胶质细胞损伤的作用及机制.方法:根据处理条件不同分为空白组(PBS处理)、血红蛋白组(血红蛋白处理)、miR-877 mimic组(血红蛋白处理,并转染miR-877 mimic)、miR-877 mimic NC组(血红蛋白处理,并转染miR-877 mimic NC).采用实时荧光定量聚合酶链式反应(RT-qPCR)检测SD大鼠星形胶质细胞miR-877表达水平;用Western blotting检测与细胞凋亡有关的蛋白(TLR4、NF-κB、Bax、B
目的:探讨麻醉诱导剂依托咪酯(Eto)在缺氧/复氧(H/R)后心肌细胞炎性损伤中的作用及其对高迁移率族蛋白B1/晚期糖基化终末产物受体/核因子κB(HMGB1/RAGE/NF-κB)通路的影响和机制.方法:随机将大鼠H9C2心肌细胞分成对照组、H/R组、Eto-L组(2 mg/L Eto预处理)、Eto-H组(4 mg/L Eto预处理)、正丁酸钠组(10 mmol/L HMGB1抑制剂正丁酸钠100μL)、Eto-H+正丁酸钠组;通过缺氧7 h后复氧2 h建立H/R心肌细胞模型,于造模前在Eto-L组、